EverHint Signal — EMA10 × Price × MACD (5 stocks) — January 07, 2026

What This Signal Is (Quick)

The EMA10 × Price × MACD strategy identifies stocks where two bullish signals occur simultaneously on the same day:

1. Price crosses above EMA10 from below

   • Yesterday: Price was at or below EMA10
   • Today: Price breaks above EMA10
   • Signals: Price momentum accelerating above short-term trend

2. MACD Line crosses above Signal Line from below

   • Yesterday: MACD Line was at or below Signal Line
   • Today: MACD Line breaks above Signal Line
   • Confirms: Bullish momentum shift at the indicator level

Why Dual Confirmation Matters:
Single crossovers can be noisy—price whipsaws above/below EMA10 constantly, and MACD oscillates frequently. By requiring both crossovers on the same day, we filter for higher-conviction setups where price action and momentum indicators align. This reduces false signals but also means fewer total signals (typically 5-20 per day vs. 20-40 for single-indicator strategies).

Key Characteristics:

• Buy signals only - This strategy generates only bullish signals (no sell signals)
• Higher quality, lower quantity - Dual confirmation means fewer but stronger setups
• Fast response - EMA10 catches early momentum shifts (vs. EMA50 or SMA200)
• Swing trading focus - Ideal for 1-4 week holding periods

This is an experimental scanner scanning the entire market for simultaneous momentum breakouts. Best used as a starting point for further research, not a standalone trading system.

How We Ranked Today (Reader Version)

We ranked signals by RSI(14) (ascending)—lower RSI values indicate more oversold conditions, making them potentially better buy entries for mean reversion within an uptrend. A stock that's crossed above EMA10 and MACD while still relatively oversold (RSI 50-60) has more room to run than one already overbought (RSI >70).

We overlaid three additional data points:

• Insider Net (USD): Net insider buying/selling over last 90 days (purchases minus sales; excludes awards/exercises)
• Days → Earnings: Calendar days until next earnings report
• Market Cap: Company size in billions/millions

Critical Context: These are momentum breakout signals, not value plays. The stocks are accelerating upward—the question is whether they're early in the move (lower RSI) or late (higher RSI). Tighter stops are essential since momentum can reverse quickly.

Important: These signals are for educational use and back-testing. This is not financial advice. See our disclaimer and FAQs.

📈 Buy-Side Signals

5 Signals Detected (Ranked by RSI → Lower = More Oversold)

Field Notes

RSI Context:
All signals fall into the neutral-to-mildly-bullish RSI range (56-70)—not oversold (<40), not overbought (>80). This is typical for momentum breakouts: stocks cross above EMA10/MACD after building bases, not during capitulation lows. BKH (56.88) and EQT (58.44) offer the best risk/reward as they're breaking out from more oversold levels with room to run. GLUE (70.34) is already extended—proceed with caution.

MACD Histogram Strength:
The MACD histogram measures the gap between MACD Line and Signal Line—larger positive values indicate stronger bullish momentum:

• GLUE (+0.341): Strongest momentum—MACD Line blasted through Signal Line decisively
• ABBV (+0.123): Solid momentum—clear bullish crossover
• CRNX (+0.038): Moderate momentum—cleaner breakout than ABBV but less conviction
• BKH (+0.022): Weak momentum—barely crossed above zero; early-stage signal
• EQT (+0.006): Very weak momentum—MACD still negative territory despite crossover

⚠️ Warning on weak MACD: BKH and EQT show MACD crossovers but histogram values near zero. These are early-stage signals—they may abort if momentum doesn't follow through quickly. Monitor closely.

Sector Breakdown:

• Healthcare (3): ABBV, CRNX, GLUE—healthcare leading with 60% of signals
• Utilities (1): BKH—defensive positioning
• Energy (1): EQT—natural gas exposure

Healthcare dominance suggests sector rotation into defensive/high-quality names. Utilities (BKH) reinforces this defensive theme.

Insider Activity:
No significant insider activity across all 5 signals. CRNX shows one M-Exempt transaction (stock option exercise) on Dec 18, but this is routine compensation, not open-market buying. Zero net insider buying or selling means insiders aren't voting with their wallets—neutral signal.

Earnings Proximity:

• ABBV (23 days): Earnings Jan 30—closest to event risk. AbbVie will report FY/Q4 2025 results before market open.
• BKH (28 days): Earnings Feb 4—moderate runway
• EQT (41 days): Earnings Feb 17—safe distance
• CRNX (50 days): Earnings Feb 26—safe distance
• GLUE (71 days): Earnings Mar 19—furthest out

Risk: ABBV's earnings are 23 days away—volatility may increase as Jan 30 approaches. BKH (28 days) also faces near-term event risk. Plan your exits accordingly.

Recent Headlines: Buy-Side Signals

ABBV (AbbVie Inc.) - MAJOR NEWS:

• "AbbVie in talks to buy biotech Revolution Medicines" (Jan 7, WSJ/Reuters): AbbVie in advanced talks to acquire cancer-drug developer Revolution Medicines, valued around $16 billion. This is a major M&A move to bolster ABBV's oncology pipeline as Humira (rheumatoid arthritis blockbuster) faces biosimilar erosion. Market reacted positively—ABBV up 5.94% on Jan 7 after falling -3.98% on Jan 5.
• Earnings Call Scheduled: AbbVie will announce FY/Q4 2025 results on Feb 4, 2026 before market open. J.P. Morgan Healthcare Conference presentation also scheduled.
• Analyst Coverage: Zacks highlighted ABBV as a "medical stock to take advantage of now" with earnings ESP potential. Forbes noted ABBV has exhibited 50%+ rallies in 2-month periods historically.

EQT (EQT Corporation):

• No recent news in provided data. EQT is a major natural gas producer with exposure to Appalachian Basin. Stock crossed above EMA10/MACD on Jan 7 with weak momentum (MACD histogram +0.006). Price still below long-term trend (SMA200 at $54.28 vs. price $54.49)—just barely above.

CRNX (Crinetics Pharmaceuticals, Inc.):

• No recent news in provided data. CRNX is a clinical-stage biotech focused on endocrine diseases (acromegaly, Cushing's disease). Stock surged 16.07% on Jan 7 after crossing above EMA10 (from $45.95 to $53.34). RSI at 60.99 suggests room to run. Earnings 50 days out (Feb 26) provides runway.

BKH (Black Hills Corporation):

• No recent news in provided data. BKH is a vertically integrated utility serving electric/gas customers in the Mountain West and Great Plains. Defensive play with 3.5%+ dividend yield. RSI at 56.88 (most oversold signal) suggests early-stage breakout. MACD histogram weakest at +0.022—needs follow-through.

GLUE (Monte Rosa Therapeutics, Inc.):

• No recent news in provided data. GLUE is a clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and other diseases. Stock jumped 45.42% on Jan 7 (from $16.01 to $23.28), triggering dual crossover. RSI at 70.34 (most extended)—caution warranted. MACD histogram strongest at +0.341 confirms explosive momentum, but entry here is late.

Vlad's Take (EverHint)

Market Backdrop (January 7, 2026):
S&P 500 -0.35%, Nasdaq +0.17%, Dow -1.04%. Mixed sentiment with tech marginally outperforming while blue chips lagged. VIX closed at 15.38 (+2.88%)—elevated above the 15 threshold, signaling caution. Small-caps (Russell 2000) underperformed at -0.46%, suggesting defensive positioning. Treasury yields rose slightly (10Y at 4.138%), applying mild pressure to growth names. Bitcoin fell -2.89% to $91,003, Ethereum dropped -4.60% to $3,144—crypto weakness reflects broader risk-off rotation.

Overall: Choppy, cautious environment. Not risk-on or risk-off extreme, but enough cross-currents to demand tighter risk management on momentum plays.

On Today's EMA10 × Price × MACD Signals:

We caught only 5 dual-crossover signals—a low count reflecting the strategy's selectivity. When you require both price and MACD to cross simultaneously, you filter out a lot of noise but also miss standalone breakouts. Today's batch is quality-focused: large-caps (ABBV $412B), mid-caps (EQT $34B, BKH $5.2B, CRNX $5.1B), and one small-cap (GLUE $1.5B).

Key Observations:

1. Healthcare dominance (3 of 5) signals sector rotation. ABBV, CRNX, GLUE all triggered buy signals on the same day. ABBV's $16B acquisition announcement is the headline catalyst—market's rewarding M&A activity in biopharma. CRNX and GLUE are clinical-stage biotechs riding sector momentum. If you're bullish on healthcare, this is your basket. If not, be cautious—biotech can reverse violently.

2. ABBV is the anchor play here. $412B market cap, 3.5%+ dividend yield, established cash flows from immunology (Skyrizi, Rinvoq) offsetting Humira biosimilar losses. The Revolution Medicines acquisition adds oncology exposure. RSI at 63.63 (neutral), MACD histogram +0.123 (solid momentum). Earnings in 23 days create near-term volatility risk, but ABBV has historically delivered strong Q4 results. This is the only signal I'd consider buying on the open.

3. EQT and BKH are weak signals. Both show MACD histograms near zero (+0.006 for EQT, +0.022 for BKH)—barely crossed above signal line. These are early-stage breakouts that may abort if momentum doesn't materialize. EQT's at $54.49 vs. SMA200 of $54.28—just 0.4% above long-term trend. BKH's a utility with low beta—won't move fast. Skip these unless you're hunting for defensive plays.

4. CRNX and GLUE are biotech lottery tickets. CRNX surged 16%, GLUE ripped 45% on Jan 7. Both are clinical-stage companies—high risk, high reward. CRNX's RSI at 60.99 suggests room to run; GLUE's RSI at 70.34 screams overbought. MACD histograms are strong (+0.038 for CRNX, +0.341 for GLUE), but you're buying after the move. If you chase GLUE here, you're asking for a pullback. CRNX is marginally better but still extended.

5. No insider buying is a yellow flag. Not one signal shows net insider purchases. Insiders aren't buying these dips/breakouts. This doesn't mean the signals are bad—it just means insiders aren't adding conviction. In a choppy market (VIX 15.38), I want to see insider buying to confirm the move. We don't have it.

Trading Plan for EMA10 × Price × MACD:

Entry Timing:

• ABBV: Wait for a retest of EMA10 ($227.74) or yesterday's close ($223.93). Don't chase $233.43—you're buying 4% above EMA10. If it pulls back to $228-230, that's your entry zone.
• CRNX: Already extended. Wait for RSI to cool below 55 or price to retest EMA10 at $48.41. Current price $53.34 is 10% above EMA10—too stretched.
• GLUE: Skip it. RSI 70.34, price 45% above yesterday. If you must trade it, wait for a 30%+ pullback to $18-20.
• BKH/EQT: Only if you're hunting defensive plays. Enter on any weakness, but keep stops tight—MACD momentum is weak.

Position Sizing:

• ABBV: 2-3% of portfolio max. It's the only large-cap with fundamental catalysts (M&A, earnings in 23 days).
• CRNX/GLUE: 0.5-1% max. Biotech is binary—these can double or halve quickly.
• BKH/EQT: 1-2% max. Low conviction—defensive hedges only.

Stop Loss:

• Price-based stop: Below yesterday's low or EMA10, whichever is lower. For ABBV, that's $223.93 (yesterday's close) or $227.74 (EMA10)—use $223.90 as your stop (3.9% risk from $233.43).
• MACD-based stop: If MACD Line crosses back below Signal Line (negative histogram), exit immediately. Momentum reversal = failed signal.

Take Profit:

• Target 1: Previous swing high or resistance level (check daily chart). For ABBV, prior high was ~$240 in December—take 50% off there (+2.8% gain).
• Target 2: SMA200 if stock is below it, or next Fibonacci extension level. Trail stop to lock in gains.
• Time stop: Exit if no upward progress in 5-7 days. EMA10 crossovers are short-term signals—don't hold through consolidation.

Risk Warning:
Dual crossovers can fail if momentum doesn't follow through. Check the broader market context:

• If S&P breaks below 6,900, momentum plays will stall.
• If VIX spikes above 20, tighten stops—volatility kills momentum trades.
• If ABBV's earnings disappoint (Jan 30), expect 10%+ downside—plan your exit before then.

Specific Picks:

• Best setup: ABBV on a pullback to $228-230. Quality name, M&A catalyst, decent RSI (63.63).
• Avoid: GLUE (too extended), EQT/BKH (weak momentum).
• Watch: CRNX if RSI cools to 55-58. Still risky, but cleaner entry than GLUE.

The market's telling you to be selective, not aggressive. Five signals is thin—respect that. Focus on ABBV, skip the rest unless you're a biotech speculator or defensive investor.

🔥 If this breakdown was useful, feel free to like, share, or subscribe. Every bit of support matters.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/